Adcock Ingram Breaks Into Biosimilars With Infliximab
As Pandemic Disrupts Annual Prescription Sales
South African firm Adcock Ingram has described the launch of Celltrion’s Remsima (infliximab) biosimilar as “a really good step for us,” as it saw volumes plunge for its Prescription business during its financial year ended 30 June.
